Sabrina Serani

Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for broader applications.

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic pancreatic cancer patients.

New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, improving patient outcomes significantly.

AbbVie seeks FDA approval for a groundbreaking oral treatment combining venetoclax and acalabrutinib, promising a new era in CLL care.

MAIA Biotechnology's ateganosine gains FDA fast track status, offering hope for advanced NSCLC patients with limited treatment options.

Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a prognostic biomarker.

Home-based mitomycin treatment shows promise for bladder cancer patients, enhancing convenience and reducing healthcare burdens while maintaining safety and efficacy.

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic benefits during treatment.

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.

A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited treatment options.

FDA prioritizes review of tabelecleucel, a promising therapy for relapsed EBV+ PTLD, offering hope to patients with limited treatment options.

A recent study highlights the rising yet inadequate rates of biomarker testing in advanced cancers, emphasizing the need for improved access to optimize patient outcomes.

Verastem Oncology's VS-7375 receives FDA fast track designation, offering hope for targeted treatment in KRAS G12D-mutated pancreatic cancer.

Mariam Eskander, MD, explores how food insecurity and geographic barriers hinder breast cancer trial participation, highlighting urgent needs for systemic change.

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with promising efficacy and safety profiles.

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, offering hope for patients with limited options.

Zydus Lifesciences gains FDA tentative approval for generic ibrutinib, enhancing access to vital cancer treatment for patients with CLL, SLL, and WM.

New findings confirm that partial-breast and reduced-dose radiotherapy effectively treat low-risk early-stage breast cancer with fewer side effects.

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete response letter.

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

Luspatercept shows promise in improving anemia in myelofibrosis patients, despite not meeting primary trial endpoints, highlighting ongoing treatment challenges.

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits in hard-to-treat cancers.

Preliminary results from the TRIFOUR trial highlight nadunolimab's potential in treating advanced triple-negative breast cancer, showing promising efficacy and safety.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Osimertinib plus chemotherapy significantly improves overall survival in EGFRm NSCLC, signaling a new standard of care.

Innovative research explores targeted therapies for early triple-negative breast cancer, aiming to reduce toxicity while enhancing treatment efficacy.

FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in oncology therapy approvals.

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for patients with limited options.

FDA grants orphan drug designation to ICT01, a promising immunotherapy for acute myeloid leukemia, targeting unmet needs in older patients.